Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE2355.7564.2 (+2.8 %)

PREV CLOSE ( ) 2291.55

OPEN PRICE ( ) 2359.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8620

TODAY'S LOW / HIGH ( )2340.00 2405.00

52 WK LOW / HIGH ( )1275.05 2649.95

NSE2359.5572.55 (+3.17 %)

PREV CLOSE( ) 2287.00

OPEN PRICE ( ) 2385.00

BID PRICE (QTY) 2359.55 (749)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 126099

TODAY'S LOW / HIGH( ) 2342.00 2401.35

52 WK LOW / HIGH ( )1277.1 2524

Select year

(Rs.in Million)

Particulars

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Mar 2019

Profit Before Tax

8414.94

24756.48

7230.95

6472.46

6539.70

Adjustment

-400.03

-16364.84

-256.41

131.71

-313.63

Changes In working Capital

-457.46

1198.72

457.46

440.68

-41.93

Cash Flow after changes in Working Capital

7557.46

9590.36

7432.00

7044.85

6184.14

Cash Flow from Operating Activities

4842.25

8107.48

5779.11

4905.00

4094.87

Cash Flow from Investing Activities

8078.51

-4055.08

4180.26

-568.43

-1534.53

Cash Flow from Financing Activities

-15433.23

-5242.42

-6955.60

-4276.22

-3583.59

Net Cash Inflow / Outflow

-2512.46

-1190.02

3003.78

60.35

-1023.25

Opening Cash & Cash Equivalents

2861.87

4051.89

1048.12

987.77

2011.02

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

349.41

2861.87

4051.89

1048.12

987.77